Type 2 Diabetes

GLP‑1 receptor agonists and dual agonists like tirzepatide have become indispensable in managing type 2 diabetes and obesity. However, their effect on gastric emptying introduces specific risks during surgery that can’t be ignored. As their use grows, the need for clear, coordinated GLP‑1 perioperative management is more important than ever. …

Sleep and diabetes are more connected than ever before. According to the newly released 2025 guidelines, sleep has officially joined nutrition and exercise as a core pillar of cardiometabolic health. Why? Because science shows that poor sleep isn’t just tiring — it can directly impact blood sugar levels, insulin resistance, …

The CKM framework in diabetes care—focusing on cardiovascular, kidney, and metabolic health—is more than a trend. It’s a clinical necessity. The ADA’s 2025 Standards of Care urge clinicians to manage these overlapping risks together, not separately. Why? Because patients with diabetes deserve outcomes that go beyond just A1C. This article …

As diabetes technology evolves at lightning speed, clinics are under increasing pressure to evaluate a growing range of tools—from continuous glucose monitors (CGMs) and insulin pumps to smartphone apps and cloud platforms. But how can healthcare providers make safe, informed decisions about which tools to recommend? A clear, structured diabetes …

Diabetes technology safety has become a critical focus as continuous glucose monitors (CGMs), insulin pumps, and automated insulin delivery systems transform diabetes care. These tools improve glycemic outcomes, enhance quality of life, and support proactive management. However, with increased device complexity comes a unique set of risks clinicians must recognize …

As GLP‑1 drugs become more widely used for managing type 2 diabetes and obesity, concerns about access disparities have intensified. Unequal distribution and affordability threaten to create a two-tier healthcare system—where only those with greater means receive these life-changing therapies. In this article, we explore the concept of GLP‑1 access …

Obesity is no longer just a lifestyle issue — it’s now globally recognized as a chronic, relapsing disease. In a bold move, the World Health Organization (WHO) has formally endorsed GLP‑1 therapy obesity treatments for long-term management in adults. This policy shift holds significant implications for diabetes care, especially as …

Effective diabetes care doesn’t happen in isolation. With millions of Americans living with diabetes, managing this chronic disease requires more than just a single doctor’s input. Team based diabetes care brings together primary care providers, pharmacists, dietitians, educators, and community health workers to create a more personalized and coordinated approach. …

In many parts of the world, cutting-edge tools for diabetes care—like continuous glucose monitors (CGMs), GLP-1 receptor agonists, and frequent laboratory monitoring—are simply not available or affordable. This article focuses on diabetes management in low resource settings, where clinicians and patients must rely on practical, evidence-based, yet low-cost strategies. For …

The future of diabetes care hinges on personalized support—and that includes updates to how we educate and empower patients. With the American Diabetes Association’s (ADA) 2025 Standards of Care redefining the framework, education for self-managing diabetes in 2026 is no longer a one-time intervention but a lifelong journey. Clinicians, educators, …